help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2007-1191
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dekkers, O. M.
Right arrow Articles by Vandenbroucke, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dekkers, O. M.
Right arrow Articles by Vandenbroucke, J. P.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Neuroendocrinology and Pituitary
Right arrow Endocrine Oncology
The Journal of Clinical Endocrinology & Metabolism Vol. 93, No. 1 61-67
Copyright © 2008 by The Endocrine Society

Mortality in Acromegaly: A Metaanalysis

O. M. Dekkers, N. R. Biermasz, A. M. Pereira, J. A. Romijn and J. P. Vandenbroucke

Departments of Endocrinology and Metabolic Diseases (O.M.D., N.R.B., A.M.P., J.A.R.) and Clinical Epidemiology (O.M.D., J.P.V.), Leiden University Medical Center, 2300 RC Leiden, The Netherlands

Address all correspondence and requests for reprints to: O. M. Dekkers, M.D., M.A., Department of Endocrinology and Metabolic Diseases C4-R, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands. E-mail: o.m.dekkers{at}lumc.nl.

Context: Several studies have assessed mortality risk in patients treated for acromegaly. All studies found a mortality that was higher than expected for the general population, but most of these increases were not statistically significant. For this reason, it is not formally established whether mortality in acromegaly is different from the general population.

Objective: The objective of the study was to address the all-cause mortality risk in patients with acromegaly.

Design: The study was a metaanalysis.

Methods: Sixteen studies on mortality in patients with acromegaly were included. The principal outcome of the metaanalysis was the weighted average of the standardized mortality ratio (SMR) of all studies. In addition, we performed a subgroup analysis of studies in which more than 80% of the patients were treated by transsphenoidal approach.

Results: The weighted mean of the SMR from all 16 studies was 1.72 (95% confidence interval 1.62–1.83). In studies with transsphenoidal surgery as the primary therapy, the weighted mean of the SMR was 1.32 (95% confidence interval 1.12–1.56).

Conclusions: This metaanalysis shows increased all-cause mortality in acromegalic patients, compared with the general population, even after transsphenoidal surgery.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
M. Sherlock, R. C. Reulen, A. A. Alonso, J. Ayuk, R. N. Clayton, M. C. Sheppard, M. M. Hawkins, A. S. Bates, and P. M. Stewart
ACTH Deficiency, Higher Doses of Hydrocortisone Replacement, and Radiotherapy Are Independent Predictors of Mortality in Patients with Acromegaly
J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4216 - 4223.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Colao, R. S. Auriemma, M. Galdiero, G. Lombardi, and R. Pivonello
Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective Study
J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 3746 - 3756.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
C L Ronchi, C Giavoli, E Ferrante, E Verrua, S Bergamaschi, D I Ferrari, S Corbetta, L Montefusco, M Arosio, B Ambrosi, et al.
Prevalence of GH deficiency in cured acromegalic patients: impact of different previous treatments
Eur. J. Endocrinol., July 1, 2009; 161(1): 37 - 42.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Melmed, A. Colao, A. Barkan, M. Molitch, A. B. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, et al.
Guidelines for Acromegaly Management: An Update
J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1509 - 1517.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
N. Friedrich, R. Haring, M. Nauck, J. Ludemann, D. Rosskopf, E. Spilcke-Liss, S. B. Felix, M. Dorr, G. Brabant, H. Volzke, et al.
Mortality and Serum Insulin-Like Growth Factor (IGF)-I and IGF Binding Protein 3 Concentrations
J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1732 - 1739.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
N. Moller and J. O. L. Jorgensen
Effects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human Subjects
Endocr. Rev., April 1, 2009; 30(2): 152 - 177.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Sherlock, E. Fernandez-Rodriguez, A. A. Alonso, R. C. Reulen, J. Ayuk, R. N. Clayton, G. Holder, M. C. Sheppard, A. Bates, and P. M. Stewart
Medical Therapy in Patients with Acromegaly: Predictors of Response and Comparison of Efficacy of Dopamine Agonists and Somatostatin Analogues
J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1255 - 1263.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Beckers
Does Preoperative Somatostatin Analog Treatment Improve Surgical Cure Rates in Acromegaly? A New Look at an Old Question
J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 2975 - 2977.
[Full Text] [PDF]


Home page
Eur J EndocrinolHome page
I M Holdaway, M J Bolland, and G D Gamble
A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly
Eur. J. Endocrinol., August 1, 2008; 159(2): 89 - 95.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society